Evidence
BMC Neurol. 2024 Jul 30;24(1):266. doi: 10.1186/s12883-024-03691-3.
ABSTRACT
The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson’s Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.
PMID:39080589 | DOI:10.1186/s12883-024-03691-3
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Evidence Blueprint
Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
